Histone deacetylase inhibitors induce VHL and ubiquitin-independent proteasomal degradation of hypoxia-inducible factor 1α

Molecular and Cellular Biology

Volumn 26, Issue 6, 2006, Pages 2019-2028

  Kong, Xianguo ^a   Lin, Zhao ^a   Liang, Dongming ^a   Fath, Donna ^a   Sang, Nianli ^a,b   Caro, Jaime ^a,b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENIC FACTOR; ENZYME; HEAT SHOCK PROTEIN 70; HEAT SHOCK PROTEIN 90; HISTONE DEACETYLASE; HISTONE DEACETYLASE 6; HISTONE DEACETYLASE INHIBITOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PROTEASOME; PROTEIN P53; SUBEROYLANILIDE HYDROXAMIC ACID; TRICHOSTATIN A; UBIQUITIN; UNCLASSIFIED DRUG; VON HIPPEL LINDAU PROTEIN;

ADAPTATION; ANAEROBIC METABOLISM; ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENCY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HYPOXIA; METASTASIS; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; TUMOR GROWTH; UBIQUITINATION;

CELL HYPOXIA; ENZYME INHIBITORS; HISTONE DEACETYLASES; HSP70 HEAT-SHOCK PROTEINS; HUMANS; HYDROXAMIC ACIDS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN STRUCTURE, TERTIARY; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN; VON HIPPEL-LINDAU TUMOR SUPPRESSOR PROTEIN;

EID: 33644780111     PISSN: 02707306     EISSN: None     Source Type: Journal    
DOI: 10.1128/MCB.26.6.2019-2028.2006     Document Type: Article

References (55)

1. Arnesen, T., D. Anderson, C. Baldersheim, M. Lanotte, J. E. Varhaug, and J. R. Lillehaug. 2004. Identification and characterization of the human ARD1-NATH protein acetyltransferase complex. Biochem. J. 386:433-443.
2. Arnesen, T., X. Kong, R. Evjenth, D. Gromyko, J. E. Vargaug, Z. Lin, N. Sang, J. Caro, and J. R. Lillehaug. 2005. Interaction between HIF1α (ODD) and hARD1 does not induce acetylation and destabilization of HIF1α. FEBS Lett. 579:6428-6432.
3. Asher, G., P. Tsvetkov, C. Kahana, and Y. Shaul. 2005. A mechanism of ubiquitin-independent proteasomal degradation of the tumor-suppressors p53 and p73. Genes Dev. 19:316-321.
4. Bali, P., M. Pranpat, J. Bradner, M. Balasis, W. Fiskus, F. Guo, K. Rocha, S. Kumaraswamy, S. Boyapalle, P. Atadja, E. Seto, and K. Bhalla. 2005. Inhibition of histone deacetylase 6 acetylates and disrupts the chaperone function of heat shock protein 90: a novel basis for antileukemia activity of histone deacetylase inhibitors. J. Biol. Chem. 280:26729-26734.
5. Bilton, R., N. Mazure, E. Trottier, M. Hattab, M. A. Dery, D. E. Richard, J. Pouyssegur, and M. C. Brahimi-Horn. 2005. Arrest-defective-1 protein, an acetyltransferase, does not alter stability of hypoxia-inducible factor (HIF)-1α and is not induced by hypoxia or HIF. J. Biol. Chem. 280:31132-31140.
6. Bramihi-Horn, C., N. Mazure, and J. Pouyssegur. 2005. Signaling via the hypoxia-inducible factor-1alpha requires multiple posttranslational modifications. Cell. Signal. 17:1-9.
7. Cho, S., Y. J. Choi, J. M. Kim, S. T. Jeong, J. H. Kim, S. H. Kim, and S. E. Ryu. 2001. Binding and regulation of HIF-1alpha by a subunit of the proteasome complex, PSMA7. FEBS Lett. 498:62-66.
8. Chowdary, D. R., J. J. Dermody, K. K. Jha, and H. L. Ozer. 1994. Accumulation of p53 in a mutant cell line defective in the ubiquitin pathway. Mol. Cell. Biol. 14:1997-2003.
9. Cockman, M. E., N. Masson, D. Mole, P. Jaakola, G. W. Chang, S. C. Clifford, E. R. Maher, C. Pugh, P. J. Ratcliffe, and P. H. Maxwell. 2000. Hypoxia inducible factor-alpha binding and ubiquitylation by the von Hippel-Lindau tumor suppressor protein. J. Biol. Chem. 275:25733-25741.
10. Covello, K. L., and M. C. Simon. 2004. HIFs, hypoxia, and vascular development. Curr. Top. Dev. Biol. 62:37-54.
11. Drummond, D. C., C. O. Noble, D. B. Kirpotin, Z. Guo, G. K. Scott, and C. C. Benz. 2005. Clinical development of histone deacetylase inhibitors as anticancer agents. Annu. Rev. Pharmacol. Toxicol. 45:495-528.
12. Evans, S. M., and C. J. Koch. 2003. Prognostic significance of tumor oxygenation in humans. Cancer Lett. 195:1-16.
13. Fisher, T. S., S. Des Etages, L. Hayes, K. Crimin, and B. Li. 2005. Analysis of ARD1 function in hypoxia response using retroviral RNA interference. J. Biol. Chem. 280:17749-17757.
14. Fukuda, R., K. Hirota, F. Fan, Y. D. Jung, L. M. Ellis, and G. L. Semenza. 2002. Insulin-like growth factor 1 induces hypoxia-inducible factor 1-mediated vascular endothelial growth factor expression, which is dependent on MAP kinase and phosphatidylinositol 3-kinase signaling in colon cancer cells. J. Biol. Chem. 277:38205-38211.
15. Gaczynska, M., and P. A. Osmuslki. 2005. Small-molecule inhibitors of proteasome activity. Methods Mol. Biol. 301:3-22.
16. George, P., P. Bali, S. Annavarapu, A. Scuto, W. Fiskus, F. Guo, C. Sigua, G. Sondarva, L. Moscinski, P. Atadja, and K. Bhalla. 2005. Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3. Blood 105:1768-1776.
17. Giaccia, A., B. G. Siim, and R. S. Johnson. 2003. HIF-1 as a target for drug development. Nat. Rev. Drug Discov. 2:803-811.
18. Harris, A. L. 2002. Hypoxia-a key regulatory factor in tumour growth. Nat. Rev. Cancer 2:38-47.
19. 2-dependent degradation domain via the ubiquitin-proteasome pathway. Proc. Natl. Acad. Sci. USA 95:7987-7992.
20. Isaacs, J. S., Y. J. Jung, E. G. Mimnaugh, A. Martinez, F. Cuttitta, and L. M. Neckers. 2002. Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1 alpha-degradative pathway. J. Biol. Chem. 277:29936-29944.
21. 2 sensing. Science 292:464-468.
22. 2-regulated prolyl hydroxylation. Science 292:468-472.
23. Jeong, J. W., M-K. Bae, M. Y. Ahn, S. H. Kim, T. K. Sohn, M. H. Bae, M. A. Yoo, E. J. Song, K. J. Lee, and K. W. Kim. 2002. Regulation and destabilization of HIF-1alpha by ARD1-mediated acetylation. Cell 111:709-720.
24. Johnstone, R. W., and J. D. Licht. 2003. Histone deacetylase inhibitors in cancer therapy: is transcription the primary target? Cancer Cell 4:13-18.
25. Kallio, P. J., W. J. Wilson, S. O'Brien, Y. Makino, and L. Poellinger. 1999. Regulation of the hypoxia-inducible transcription factor 1alpha by the ubiquitin-proteasome pathway. J. Biol. Chem. 274:6519-6525.
26. Kamura, T., S. Sato, K. Iwai, M. Czyzyk-Krzeska, R.C. Conaway, and J. W. Conaway. 2000. Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex. Proc. Natl. Acad. Sci. USA 97:10430-10435.
27. Katschinski, D. M., L. Le, D. Heinrich, K. F. Wagner, S. G. Schindler, and R. H. Wenger. 2002. Heat induction of the unphosphorylated form of hypoxia-inducible factor-1alpha is dependent on HSP90 activity. J. Biol. Chem. 277:9262-9267.
28. Katschinski, D. M., L. Le, S. G. Schindler, T. Thomas, A. K. Voss, and R. H. Wenger. 2004. Interaction of the PAS B domain with HSP90 accelerates hypoxia-inducible factor-1alpha stabilization. Cell Physiol. Biochem. 14:351-360.
29. Kim, M. S., H. J. Kwon, Y. M. Lee, J. H. Baek, J. E. Jang, S. W. Lee, E. J. Moon, H. S. Kim, S. K. Lee, H. Y. Chung, C. W. Kim, and K. W. Kim. 2001. Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes. Nat. Med. 7:437-443.
30. Kim, W. Y., and W. G. Kaelin. 2004. Role of VHL gene mutation in human cancer. J. Clin. Oncol. 22:4991-5004.
31. Kovacs, J. J., P. J. Murphy, S. Gaillard, X. Zhao, J. T. Wu, C. V. Nicchitta, M. Yoshida, D. O. Toft, W. B. Pratt, and T. P. Yao. 2005. HDAC6 regulates Hsp90 acetylation and chaperone-dependent activation of glucocorticoid receptor. Mol. Cell 18:601-607.
32. Liu, C. W., E. Strickland, G. N. Demartino, and P. J. Thomas. 2005. Recognition and processing of misfolded proteins by PA700, the 19S regulatory complex of the 26S proteasome. Methods Mol. Biol. 301:71-81.
33. Liu, C. W., M. J. Corboy, G. N. DeMartino, and P. J. Thomas. 2003. Endoproteolytic activity of the proteasome. Science 299:408-411.
34. Luo, J., M. Li, Y. Tang, M. Laszkowska, R. G. Roeder, and W. Gu. 2004. Acetylation of p53 augments its site-specific DNA binding both in vitro and in vivo. Proc. Natl. Acad. Sci. USA 101:2259-2264.
35. Marks, P. A., V. M. Richon, R. Breslow, and R. A. Rifkind. 2001. Histone deacetylase inhibitors as new cancer drugs. Curr. Opin. Oncol. 13:477-483.
36. Masson, N., C. William, P. H. Maxwell, C. Pugh, and P. J. Ratcliffe. 2001. Independent function of two destruction domains in HIF1α chains activated by prolyl-hydroxylation. EMBO J. 20:5197-5206.
37. Maxwell, P. H., M. S. Wiesener, G. W. Chang, S. C. Clifford, E. C. Vaux, M. E. Cockman, C. C. Wykoff, C. W. Pugh, E. R. Maher, and P. J. Ratcliffe. 1999. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 399:271-275.
38. Mayer, M. P., and B. Bukau. 2005. Hsp70 chaperones: cellular functions and molecular mechanism. Cell. Mol. Life Sci. 62:670-684.
39. McClellan, A. J., S. Tam, D. Kaganovich, and J. Frydman. 2005. Protein quality control: chaperones culling corrupt conformations. Nat. Cell Biol. 8:736-741.
40. Metzen, E., and P. J. Ratcliffe. 2004. HIF hydroxylation and cellular oxygen sensing. Biol. Chem. 385:223-230.
41. MieLee, Y., S. H. Kim, H. S. Kim, M. JinSon, H. Nakajima, H. JeongKwon, and K. W. Kim. 2003. Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1alpha activity. Biochem. Biophys. Res. Commun. 300:241-246.
42. Murphy, P. J., Y. Morishima, J. J. Kovacs, T. P. Yao, and W. B. Pratt. 2005. Regulation of the dynamics of hsp90 action on the glucocorticoid receptor by acetylation/deacetylation of the chaperone. J. Biol. Chem. 280:33792-33799.
43. Park, E. C., and J. W. Szostak. 1992. ARD1 and NAT1 proteins form a complex that has N-terminal acetyltransferase activity. EMBO J. 11:2087-2093.
44. Ravi, R., B. Mookerjee, Z. M. Bhujwalla, C. H. Sutter, D. Artemov, Q. Zeng, L. E. Dillehay, A. Madan, G. L. Semenza, and A. Bedi. 2000. Regulation of tumor angiogenesis by p53-induced degradation of hypoxia-inducible factor 1alpha. Genes Dev. 14:34-44.
45. Salceda, S., and J. Caro. 1997. Hypoxia-inducible factor 1alpha (HIF-1alpha) protein is rapidly degraded by the ubiquitin-proteasome system under normoxic conditions. Its stabilization by hypoxia depends on redox-induced changes. J. Biol. Chem. 272:22642-22647.
46. Sang, N., J. Fang, V. Srinivas, I. Leshchinsky, and J. Caro. 2002. Carboxyl-terminal transactivation activity of hypoxia-inducible factor 1 alpha is governed by a von Hippel-Lindau protein-independent, hydroxylation-regulated association with p300/CBP. Mol. Cell. Biol. 22:2984-2992.
47. Semenza, G. L. 2003. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer. 3:721-732.
48. Stoeltzing, O., M. F. McCarty, J. S. Wey, F. Fan, W. Liu, A. Belcheva, D. Bucana, G. L. Semenza, and L. M. Ellis. 2004. Role of hypoxia-inducible factor 1alpha in gastric cancer cell growth, angiogenesis, and vessel maturation. J. Natl. Cancer Inst. 96:946-956.
49. Thornton, R. D., P. Lane, R. C. Borghaei, E. A. Pease, J. Caro, and E. Mochan. 2000. Interleukin 1 induces hypoxia-inducible factor 1 in human gingival and synovial fibroblasts. Biochem. J. 350:307-312.
50. Wegele, H., L. Muller, and J. Buchner. 2004. Hsp70 and Hsp90, a relay team for protein folding. Rev. Physiol. Biochem. Pharmacol. 151:1-44.
51. Williams, R. J. 2001. Trichostatin A, an inhibitor of histone deacetylase, inhibits hypoxia-induced angiogenesis. Expert Opin. Investig. Drugs 10:1571-1573.
52. Yancopoulos, G. D., S. Davis, N. W. Gale, J. S. Rudge, S. J. Wiegand, and J. Holash. 2000. Vascular-specific growth factors and blood vessel formation. Nature 407:242-248.
53. Yang, X. J., and S. Gregoire. 2005. Class II histone deacetylases: from sequence to function, regulation, and clinical implication. Mol. Cell. Biol. 25:2873-2884.
54. Zhong, H., G. L. Semenza, J. W. Simons, and A. M. De Marzo. 2004. Up-regulation of hypoxia-inducible factor 1alpha is an early event in prostate carcinogenesis. Cancer Detect. Prev. 28:88-93.
55. Zhou, J., T. Schmid, R. Frank, and B. Brune. 2004. PI3K/Akt is required for heat shock proteins to protect hypoxia-inducible factor 1alpha from pVHL-independent degradation. J. Biol. Chem. 279:13506-13513.